Browsing Tag
GSK
40 posts
Positive CHMP opinion sets stage for GSK’s ready-to-use Shingrix syringe approval in Europe
GSK receives CHMP green light for Shingrix prefilled syringe. Learn how this vaccine format could simplify shingles protection across Europe.
GSK stock jumps as insider Luke Miels named next CEO — can he deliver growth before HIV patent cliff hits?
GSK shares rise after naming Luke Miels as CEO-designate to succeed Emma Walmsley on Jan 1, 2026. Find out what investors expect next.
Theravance Biopharma cashes out remaining Trelegy royalties in $225m deal with GSK
Theravance Biopharma sells Trelegy royalties to GSK for $225M, unlocking shareholder value and reinforcing its focus on YUPELRI and ampreloxetine.
Phase 3 trials to watch in 2025: Why this year matters for biotech investors
Explore the top Phase 3 trials of 2025 from Eli Lilly, GSK, and Innovent Biologics — including pipeline impact, investor sentiment, and regulatory milestones.
Clover Biopharmaceuticals receives FDA clearance for RSV vaccine trial, expands respiratory disease research
Clover Biopharmaceuticals advances RSV vaccine research with FDA-approved SCB-1019 trials, targeting revaccination gaps and combination immunization strategies.
GSK secures FDA approval for 5-in-1 meningococcal vaccine to expand protection for adolescents
GSK has received approval from the US Food and Drug Administration (FDA) for PENMENVY, a 5-in-1 meningococcal vaccine…
Canada approves GSK’s Arexvy vaccine for RSV protection in adults 50-59 at elevated risk
In a crucial development for public health, Health Canada has extended its approval for GlaxoSmithKline’s Arexvy vaccine to…
Pfizer to offload 540 million shares in shocking Haleon sale—What does this mean for the healthcare giant?
In a blockbuster move set to shake up the market, Pfizer has announced its plan to sell approximately…
FDA extends approval for GSK’s RSV vaccine, AREXVY, to adults aged 50-59 at increased risk
The U.S. Food and Drug Administration (FDA) has officially broadened the age indication for GSK plc’s (LSE/NYSE: GSK)…
GSK acquires Elsie Biotechnologies for up to $50m to enhance oligonucleotide therapeutics
GSK plc (LSE/NYSE: GSK), a global healthcare leader, has completed the acquisition of Elsie Biotechnologies, a private biotechnology…